Wolfe Research Initiates Coverage On UDR with Peer Perform Rating, Announces Price Target of $56

Wolfe Research analyst Andrew Rosivach initiates coverage on UDR (NYSE:UDR) with a Peer Perform rating and announces Price Target of $56.

byBenzinga Newsdesk

June 15, 2021

1 minute read

Wolfe Research analyst Andrew Rosivach initiates coverage on UDR (NYSE:UDR) with a Peer Perform rating and announces Price Target of $56.

Stratasys Acquires Remaining Stake In Xaar 3D For Undisclosed Sum

By Anusuya Lahiri

October 6, 6:41 AM

Polymer 3D printing solutions provider Stratasys Ltd (NASDAQ:SSYS) acquired the remaining shares of Xaar 3D Ltd from Xaar PLC (OTC:XAARF), accelerating its growth in…

SSYS

Wedbush Maintains Outperform on Century Communities, Lowers Price Target to $79

By Benzinga Newsdesk

October 10, 9:18 AM

Wedbush analyst Jay McCanless maintains Century Communities (NYSE:CCS) with a Outperform and lowers the price target from $94 to $79.

CCS

Lifevantage Q4 Adj. EPS $0.01 Misses $0.14 Estimate, Sales $50.94M Beat $49.64M Estimate

By Michael Horton

August 23, 4:07 PM

Lifevantage (NASDAQ:LFVN) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.14 by 92.86 percent. This is a 96.77 percent decrease over earnings of $0.31 per share from the

LFVN

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs

By Shanthi Rexaline

June 25, 7:32 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)

ABBV

Wolfe Research Initiates Coverage On UDR with Peer Perform Rating, Announces Price Target of $56

Related Posts

Stratasys Acquires Remaining Stake In Xaar 3D For Undisclosed Sum

Wedbush Maintains Outperform on Century Communities, Lowers Price Target to $79

Lifevantage Q4 Adj. EPS $0.01 Misses $0.14 Estimate, Sales $50.94M Beat $49.64M Estimate

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs